newsfilter
← Latest News
PR Newswire·

BioArctic and Mesenkia enter oncology research collaboration

  • BioArctic AB & Mesenkia Therapeutics signed a research collaboration agreement on August 19, 2026, to develop a novel antibody-based approach for glioblastoma.
  • The project combines BioArctic's BrainTransporter™ technology with Mesenkia's KITAIbodies® platform to target the HVEM protein on glioblastoma tumor cells & tumor stem cells.
  • BioArctic will generate a novel drug candidate by integrating its delivery technology with Mesenkia's antibody, followed by preclinical studies to validate the concept.
  • This partnership expands BioArctic's pipeline into oncology beyond its core expertise in neurodegenerative diseases & aims to address the challenge of delivering large molecules across the blood-brain barrier.
  • CEOs Gunilla Osswald (BioArctic) & Moa Fransson (Mesenkia) stated the collaboration seeks to overcome treatment resistance & improve outcomes for patients with this aggressive brain cancer.